Author

Peter Dynoodt

Observed names: P Dynoodt, P. Dynoodt, PETER DYNOODT

Observed institutions: University College Dublin, Lund University, Trinity College Dublin, Ghent University Hospital, OncoMark (Ireland), St. Vincent's University Hospital, Skåne University Hospital, KU Leuven

ORCID: 0000-0003-0892-4200

Observed ORCID: 0000-0003-0892-4200

OpenAlex ID: A5004356371

Griscelli syndrome: a model system to study vesicular trafficking

2009 · Mireille Van Gele, Peter Dynoodt, et al. · Pigment Cell & Melanoma Research · 192

Identification of miR-145 as a Key Regulator of the Pigmentary Process

2012 · Peter Dynoodt, Pieter Mestdagh, et al. · Journal of Investigative Dermatology · 125

PDF

Lipid-mediated gene delivery to the skin

2011 · Barbara Geusens, Tine Strobbe, et al. · European Journal of Pharmaceutical Sciences · 114

Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma

2017 · Jasper Wouters, Miguel Vizoso, et al. · BMC Medicine · 105

PDF

miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells

2013 · PETER DYNOODT, REINHART SPEECKAERT, et al. · International Journal of Oncology · 84

PDF

Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer

2017 · Linda Zuurbier, Arman Rahman, et al. · Oncotarget · 52

PDF

Low expression of pro-apoptotic proteins Bax, Bak and Smac indicates prolonged progression-free survival in chemotherapy-treated metastatic melanoma

2020 · Cristiano Guttà, Arman Rahman, et al. · Cell Death and Disease · 50

PDF

Prognostic and predictive biomarkers in melanoma: an update

2015 · Mona Foth, Jasper Wouters, et al. · Expert Review of Molecular Diagnostics · 25

Validation of the OncoMasTR Risk Score in Estrogen Receptor–Positive/HER2-Negative Patients: A TransATAC study

2019 · Richard Buus, Ivana Sestak, et al. · Clinical Cancer Research · 15

PDF

Development of a 3D pigmented skin model to evaluate RNAi‐induced depigmentation

2011 · Mireille Van Gele, Barbara Geusens, et al. · Experimental Dermatology · 11

PDF

Analytical Validation of a Novel 6-Gene Signature for Prediction of Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative, Early-Stage Breast Cancer

2022 · Tony Loughman, Stephen Barron, et al. · Clinical Chemistry · 8

PDF

Prognostic value of the 6-gene OncoMasTR test in hormone receptor–positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors

2021 · Seodhna M. Lynch, Niamh M. Russell, et al. · European Journal of Cancer · 5

PDF

Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer

2018 · T. Loughman, A. Chan-Ju Wang, et al. · Annals of Oncology · 4

Additional prognostic value of OncoMasTR multigene prognostic signature to clinicopathological information in patients with HR-positive, HER2-negative, lymph node-negative breast cancer from the TAILORx Tissue Bank, Ireland.

2019 · Darran O'Connor, Catherine Margaret Kelly, et al. · Journal of Clinical Oncology · 3

Synthesis and characterization of non-viral liposomal carriers for the local application of siRNA molecules and anti-miRNAs in the therapeutic treatment of psoriasis

2011 · Stefanie Bracke, Barbara Geusens, et al. · Journal of Translational Medicine · 3

PDF

Evaluation of the OncoMasTR prognostic signature in postmenopausal women with primary ER-positive breast cancer.

2018 · Ivana Sestak, Richard Buus, et al. · Journal of Clinical Oncology · 2

PDF

Comparison of the prognostic performance between OncoMasTR and OncotypeDX multigene signatures in hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.

2018 · Catherine Margaret Kelly, John Crown, et al. · Journal of Clinical Oncology · 1

Supplementary Table S4 from Validation of the OncoMasTR Risk Score in Estrogen Receptor–Positive/HER2-Negative Patients: A TransATAC study